Pharmaceuticals Germany

Germany Oral GLP-1 Drugs Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Germany Oral GLP-1 Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Germany · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $142.3 Mn Placeholder estimate
Estimate 2025 $185.2 Mn 3.3% of the global market
Projected 2034 $1.98 Bn 967.8% Adds $1.79 Bn over 9 forecast years
CAGR 2025–2034 30.1% Faster than 98% of 180 Pharmaceuticals markets here
Key players 5
  • Germany is 3.32% of the global market.
  • In Europe, the largest is Germany (this report) at $185.2 Mn.
  • Fastest growing: Russia at 31.8% a year.
  • Germany ranks 1st of 6 by size in Europe.

Market size projection

Germany

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.79 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Oral GLP-1 Drugs Market market size by year, Germany
YearMarket sizeChange that yearSince 2025
2024 (estimate) $142.3 Mn — —
2025 (base) $185.2 Mn +$42.8 Mn —
2026 (forecast) $240.9 Mn +$55.7 Mn +30.1%
2027 (forecast) $313.4 Mn +$72.5 Mn +69.3%
2028 (forecast) $407.8 Mn +$94.3 Mn +120.2%
2029 (forecast) $530.5 Mn +$122.7 Mn +186.5%
2030 (forecast) $690.2 Mn +$159.7 Mn +272.7%
2031 (forecast) $897.9 Mn +$207.7 Mn +384.9%
2032 (forecast) $1.17 Bn +$270.3 Mn +530.9%
2033 (forecast) $1.52 Bn +$351.6 Mn +720.8%
2034 (forecast) $1.98 Bn +$457.5 Mn +967.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Germany Oral GLP-1 Drugs Market Analysis at a glance
Market size, 2025$185.2 Mn placeholder estimate
Forecast, 2034$1.98 Bn placeholder estimate
Growth (CAGR), 2025–203430.1% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug, application and end user (see all)
Key playersNovo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Structure Therapeutics, Viking Therapeutics (see all)
Regulator in GermanyBfArMSource: Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Germany Oral GLP-1 Drugs Market Analysis Executive Summary

Oral GLP-1 drugs deliver GLP-1 based therapy as a tablet instead of an injection, making treatment easier for people with diabetes or obesity.

Key segments of the oral GLP-1 Drugs market include drug (Oral Semaglutide, Orforglipron and Danuglipron) and application (Type 2 Diabetes and Obesity).

Bar chart: Germany Oral GLP-1 Drugs market size, 2024–2034, placeholder estimates. $142.3 Mn in 2024, $185.2 Mn in 2025 and $1.98 Bn in 2034, 30.1% CAGR.
Germany Oral GLP-1 Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Germany Oral GLP-1 Drugs Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the oral GLP-1 Drugs market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the oral GLP-1 Drugs market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the oral GLP-1 Drugs market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Oral GLP-1 Drugs Market in Germany

The oral GLP-1 Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Oral GLP-1 Drugs Market in Germany

Oral GLP-1 Drugs in Germany: rules, payment and health figures

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by BfArM or, for vaccines and blood products, the Paul-Ehrlich-Institut.⁠[1] Most people have statutory health insurance; the Federal Joint Committee (G-BA) decides what it covers and rates the added benefit of new medicines.⁠[2] Obesity (adults): 20.6% of adults in 2024, the latest WHO figure for Germany.⁠[3]

[1] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.

[2] Federal Joint Committee (G-BA). Checked 14 Nov 2026.

[3] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 20 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for oral GLP-1 Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Germany.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Oral GLP-1 Drugs right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Oral GLP-1 Drugs in context

Germany compared

  • Obesity (adults): 20.6% of adults (2024). World: 16.2% of adults (2024). 5th highest of the 13 countries we cover in Europe.[1]
  • Health spending per person: 6,849 US$ per person (2024). World: 1,317 US$ per person (2023). 2nd highest of the 13 countries we cover in Europe.[2]
  • Doctors: 4.53 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 2nd highest of the 13 countries we cover in Europe.[3]

[1] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 19 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.

Free data on this topic

Inside Germany

Quick answers

Frequently asked questions

How big is the Oral GLP-1 Drugs market in Germany?
Placeholder estimate: about $185.2 Mn in 2025, rising to about $1.98 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Oral GLP-1 Drugs market in Germany growing?
Placeholder estimate: about 30.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Oral GLP-1 Drugs market report cover?
The report splits the market by drug (Oral Semaglutide, Orforglipron, Danuglipron, Others), application (Type 2 Diabetes, Obesity) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Oral GLP-1 Drugs market?
Key players include Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Structure Therapeutics and Viking Therapeutics.
What is driving the Oral GLP-1 Drugs market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the oral GLP-1 Drugs market.
Who regulates Oral GLP-1 Drugs in Germany?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by BfArM or, for vaccines and blood products, the Paul-Ehrlich-Institut. Source: Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
How is healthcare paid for in Germany?
Most people have statutory health insurance; the Federal Joint Committee (G-BA) decides what it covers and rates the added benefit of new medicines. Source: Federal Joint Committee (G-BA). Checked 14 Nov 2026.
What does WHO report for Germany?
Obesity (adults): 20.6% of adults in 2024, the latest WHO figure. Source: WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 20 Nov 2026.
How many people in Germany are 65 or older?
23.7% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 19 Nov 2026.
How much research is published on Oral GLP-1 Drugs?
PubMed lists 65 papers on Oral GLP-1 Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Germany

See all

Related on obesity and diabetes

See the topic